|
Group
|
PFS
|
OS
|
ORR
|
|---|
|
No.of studies
|
HR (95% CI)
|
P
|
I2 (%)
|
No.of studies
|
HR (95% CI)
|
P
|
I2 (%)
|
No.of studies
|
RR (95% CI)
|
P
|
I2 (%)
|
|---|
|
Total
|
3
|
1.06 [0.98, 1.15]
|
0.13
|
0
|
8
|
0.92 [0.79–1.07]
|
0.29
|
61
|
8
|
1.03 [0.93, 1.13]
|
0.58
|
48
|
|
Nation
|
|
USA
|
1
|
1.05 [0.90, 1.22]
|
0.53
|
NA
|
4
|
0.86 [0.77, 0.95]
|
0.004
|
28
|
2
|
1.24 [1.03, 1.51]
|
0.03
|
0
|
|
Canada
|
1
|
1.08 [0.98, 1.19]
|
0.12
|
NA
|
2
|
1.25 [0.78, 1.98]
|
0.35
|
75
|
1
|
0.91 [0.81, 1.04]
|
0.16
|
NA
|
|
Korea
|
1
|
0.91 [0.64, 1.30]
|
0.62
|
NA
|
1
|
0.70 [0.49, 0.99]
|
0.04
|
NA
|
1
|
1.57 [0.98, 2.52]
|
0.06
|
NA
|
|
Italy
|
NA
|
NA
|
NA
|
NA
|
1
|
0.94 [0.38, 2.32]
|
0.89
|
NA
|
2
|
1.28 [0.90, 1.82]
|
0.17
|
NA
|
|
UK
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
1
|
1.05 [0.35, 3.16]
|
0.93
|
NA
|
|
France
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
1
|
0.89 [0.48, 1.63]
|
0.70
|
NA
|
|
The number of pazopanib
|
|
>100
|
2
|
1.07 [0.99, 1.16]
|
0.1
|
0
|
3
|
0.93 [0.81, 1.06]
|
0.26
|
60
|
2
|
1.05 [0.78, 1.42]
|
0.73
|
85
|
|
<100
|
1
|
0.91 [0.64, 1.30]
|
0.62
|
NA
|
5
|
0.95 [0.65, 1.38]
|
0.77
|
69
|
6
|
1.25 [0.96, 1.62]
|
0.09
|
0
|
|
classification a
|
|
Poor risk
|
1
|
0.91 [0.64, 1.30]
|
0.62
|
NA
|
2
|
0.90 [0.56, 1.44]
|
0.66
|
78
|
1
|
1.57 [0.98, 2.52]
|
0.06
|
NA
|
|
Intermediate risk
|
NA
|
NA
|
NA
|
NA
|
2
|
1.36 [0.73, 2.52]
|
0.33
|
73
|
NA
|
NA
|
NA
|
NA
|
|
Mixed group
|
2
|
1.07 [0.99, 1.16]
|
0.1
|
0
|
7
|
0.95 [0.82, 1.11]
|
0.54
|
61
|
7
|
1.01 [0.91, 1.11]
|
0.85
|
43
|
|
Study design
|
|
RS
|
2
|
1.07 [0.97, 1.17]
|
0.17
|
0
|
7
|
0.93 [0.77, 1.12]
|
0.44
|
67
|
5
|
1.17 [0.85, 1.61]
|
0.33
|
58
|
|
RCT
|
1
|
1.05 [0.90, 1.22]
|
0.53
|
NA
|
1
|
0.91 [0.76, 1.08]
|
0.29
|
NA
|
3
|
1.19 [1.00, 1.43]
|
0.05
|
0
|
- Abbreviations: PFS: progression-free survival, OS: overall survival, ORR: objective response rate, HR, hazard ratio, RR: relative risk, RS: retrospective study, RCT: randomized controlled trial, NA: not available
- a Patients were classified according to the International mRCC Database Consortium (IMDC) risk group
